Voyager Therapeutics company info

What does Voyager Therapeutics do?
Voyager Therapeutics (NASDAQ:VYGR) is a dynamic biotechnology firm engaged in developing gene therapies that aim to provide life-changing treatments for severe neurological diseases. This endeavor involves a focus on creating innovative viral vector platforms to deliver genetic material directly into cells to correct or counteract diseases like Parkinson's, Huntington's, and ALS, among others. By pushing the boundaries of gene therapy, Voyager Therapeutics seeks not only to expand scientific understanding but also to translate groundbreaking research into therapies that can profoundly impact patient care and quality of life. The company's objectives are deeply rooted in a commitment to innovation, patient health, and developing sustainable treatments that address some of the most challenging medical conditions faced today.
Voyager Therapeutics company media
Company Snapshot

Is Voyager Therapeutics a public or private company?

key
Ownership
Public

How many people does Voyager Therapeutics employ?

people
Employees
162

What sector is Voyager Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Voyager Therapeutics?

location pin
Head Office
Lexington, United States

What year was Voyager Therapeutics founded?

founded flag
Year Founded
2013
What does Voyager Therapeutics specialise in?
/Gene Therapy /Neurological Treatments /VY-AADC Program /Parkinson's Disease /VY-HTT01 Project /Huntington's Disease

What are the products and/or services of Voyager Therapeutics?

Overview of Voyager Therapeutics offerings
Gene therapy programs targeting Parkinson's disease, using adeno-associated virus vectors to deliver therapeutic genes directly to the brain.
Huntington's disease gene therapy project, aimed at reducing the production of mutant huntingtin protein.
ALS gene therapy development, focusing on silencing genes responsible for ALS.
Friedreich's Ataxia targeted gene therapy, aiming to increase frataxin protein expression.
Technology platform for the development of next-generation AAV capsids, enhancing gene therapy delivery and specificity.
Collaborations with pharmaceutical companies to co-develop gene therapies for severe neurological diseases.

Who is in the executive team of Voyager Therapeutics?

Voyager Therapeutics leadership team
  • Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
    Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
    President, CEO & Director
  • Mr. Peter P. Pfreundschuh CPA
    Mr. Peter P. Pfreundschuh CPA
    Chief Financial Officer
  • Dr. Krystof  Bankiewicz M.D., Ph.D.
    Dr. Krystof Bankiewicz M.D., Ph.D.
    Founder
  • Dr. Guangping  Gao Ph.D.
    Dr. Guangping Gao Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Mark A. Kay M.D., Ph.D.
    Dr. Mark A. Kay M.D., Ph.D.
    Founder
  • Dr. Phillip D. Zamore Ph.D.
    Dr. Phillip D. Zamore Ph.D.
    Founder & Member of Scientific Advisory Board
  • Ms. Robin  Swartz
    Ms. Robin Swartz
    COO & Acting Chief Business Officer
  • Mr. Todd  Carter Ph.D.
    Mr. Todd Carter Ph.D.
    Chief Scientific Officer